Disclosed is a use of Helminthostachys zeylanica, ugonins or compounds of formula (I) for the treatment or prevention of metabolic diseases comprising at least one selected from metabolic syndrome, excessive lipid accumulation, obesity, overweight, fatty liver, hepatic steatosis, hepatitis, cirrhosis, liver cancer, dyslipidemia, hyperlipidemia, hypertriglyceridemia, hyperlipoproteinemia, hypercholesterolemia, cardiovascular disease, hyperglycemia, hyperinsulinemia, diabetes mellitus type 2, insulin resistance, insulin disorder, impaired glucose tolerance and a combination thereof.

National Research Institute of Chinese Medicine, Ministry of Health and Welfare

NATIONAL RESEARCH INSTITUTE OF CHINESE MEDICINE, MINISTRY OF HEALTH AND WELFARE

Use of helminthostachys, ugonins or flavone-based compounds for the treatment or prevention of metabolic diseases

The expression of APOBEC-1 in the liver of transgenic mice can cause liver dysplasia and liver tumors, and the expression of human APOBEC-1 in the intestine, stomach, or brain can cause obesity. Promiscuous editing of other mRNAs is correlated to these phenotypic changes. The instant invention discloses novel techniques for detecting aberrantly edited mRNAs, and hence, genes responsible for non-wild type phenotypes.

liver neoplasms/rasvumus

Use of helminthostachys, ugonins or flavone-based compounds for the treatment or prevention of metabolic diseases

Screening methods to detect mRNA targets of editing enzymes

Kõige täiuslikum ravimtaimede andmebaas, mida toetab teadus